Attorneys For Servis Say FBI Misled Court On Wiretaps, Want Evidence Suppressed

Attorneys for indicted trainer Jason Servis filed a motion on Monday in U.S. District Court for the Southern District of New York asking Judge Mary K. Vyskocil to suppress evidence obtained through Title III wiretaps on the telephones of Servis, trainer Jorge Navarro and veterinarian Kristian Rhein in connection with the March 2020 federal indictments of more than two dozen people alleged to be involved in a multi-state racehorse doping scheme.

Attorneys Rita Glavin and Michael Considine said in court filings that the FBI in seeking the wiretaps made “material misstatements and omissions” that were “deliberate or reckless” in seeking the wiretap on Servis authorized on April 30, 2019, and extended three times. The attorneys said the wiretap resulted in the “interception of thousands of communications” of Servis, one of several trainers indicted in the federal investigation that began in 2017.

First, the attorneys state, the FBI chose not to inform the court that no horses under Servis' care failed any post-race drug tests during the span of the investigation. “By contrast,” they wrote, “horses trained by Thoroughbred horse trainer Bob Baffert (who has never been criminally charged) have failed numerous post-race drug tests in the last several years, most recently failing a post-race drug test for the 2021 disqualified Kentucky Derby winner, 'Medina Spirit.'” (Editor's Note: A hearing has yet to be conducted on Medina Spirit's positive drug test and he has not been disqualified from the Derby.)

Secondly, the attorneys allege, FBI agents consistently misstated the nature of two drugs mentioned in connection with Servis: SGF-1000, a product marketed by Kentucky-based Medivet Equine, and the bronchodilator clenbuterol.

“SGF-1000 was repeatedly tested prior to the wiretap and found to contain no performance enhancing substances,” the attorneys claim, citing a number of emails between different parties and the Hong Kong Jockey Club, whose lab apparently tested the substance that is said to contain sheep collagen as a primary ingredient. Despite that, the attorneys wrote, an FBI agent seeking the original wiretap or extensions “repeatedly described SGF-1000 to the court as a 'growth factor' and 'performance enhancing substance.'”

The attorneys' memorandum in support of the motion to suppress also quotes from intercepted comments by Rhein (a part owner of Medivet) that SGF-1000 does not contain any illegal substances.  “Everything we've done is by the letter of the law,” Rhein told Servis in one conversation.

On Tuesday, Rhein pleaded guilty in federal court to administering and distributing adulterated and misbranded drugs and faces three years in prison.

“In its zeal to secure and maintain the wiretap,” the attorneys claim, “the government also misled the issuing courts about clenbuterol, wrongfully characterizing it as a performance-enhancing drug that was banned by various state regulators. In fact, clenbuterol was expressly permitted in the jurisdictions Mr. Servis' horses raced. “Although local rules of the relevant jurisdictions provide that a horse cannot race when clenbuterol is present within their system above a certain threshold at the time of a race, none of Mr. Servis' horses failed a single post-race test during the period of the government's investigation. The government withheld this fact from the issuing courts as well,” the attorneys wrote.

Their final argument claims that the FBI “misled the court about the necessity for a wiretap of Mr. Servis' phone in its requirement to explain that 'normal investigative procedures have been tried and have failed or reasonably appear to be unlikely to succeed if tried or to be too dangerous.' … The government failed to take even the most basic of investigative steps with respect to Mr. Servis, and instead ran to the District Court for a wiretap as essentially its first investigative step.”

The motion also seeks suppression of evidence from wiretaps on the phones of Rhein and Navarro, the latter of whom has asked the court for a hearing to change his “not guilty” plea.

The post Attorneys For Servis Say FBI Misled Court On Wiretaps, Want Evidence Suppressed appeared first on Horse Racing News | Paulick Report.

Source of original post

Oaklawn Renews Commitment To Clenbuterol-Free Racing

Working in partnership with the Arkansas Racing Commission and the Arkansas HBPA (Horsemen's Benevolent and Protective Association), Oaklawn has announced, subject to regulatory approval, the prohibition of Clenbuterol or any other beta2-agonist within 120 days of a race. This restriction is part of Oaklawn's ongoing commitment to enhancing the safety and integrity of its racing program.

Conducted by Industrial Labs, the presence of Clenbuterol and other beta2-agonist will be determined through blood, urine and hair follicle testing.

“Banning the use of Clenbuterol and other beta2-agonists further proves our commitment to the safety and integrity of our racing program,” said Oaklawn President Louis Cella. “Every decision we make is to enhance the experience of our horsemen and fans at Oaklawn. When we say “Racing First,' we lead by example.”

Oaklawn's 2021-2022 season runs from Friday, Dec. 3 to Sunday, May 8. The schedule features a total of 36 stakes worth $12,300,000, highlighted by the $1.25 million Arkansas Derby (G1) and three $1 million stakes races – $1 million Rebel Stakes (G2), $1 million Oaklawn Handicap (G2) and $1 million Apple Blossom Handicap (G1). All allowance races will be worth a minimum of $100,000 as part of the richest purse structure in Oaklawn's 118-year history.

The post Oaklawn Renews Commitment To Clenbuterol-Free Racing appeared first on Horse Racing News | Paulick Report.

Source of original post

Oaklawn Extends Clenbuterol Ban to 120 Days Before Race

The administration of Clenbuterol or any other beta2-agonist will be banned within 120 days of a race at the 2021-22 Oaklawn Park meet, Oaklawn announced Thursday. The rule, agreed to in partnership with the Arkansas HBPA and Arkansas Racing Commission, extends the ban from 60 days, which was the standard for last season's meet.

Conducted by Industrial Labs, the presence of Clenbuterol and other beta2-agonist will be determined through blood, urine and hair follicle testing.

“Banning the use of Clenbuterol and other beta2-agonists further proves our commitment to the safety and integrity of our racing program,” said Oaklawn President Louis Cella. “Every decision we make is to enhance the experience of our horsemen and fans at Oaklawn. When we say “Racing First,' we lead by example.”

Oaklawn's 2021-2022 season runs from Friday, Dec. 3 to Sunday, May 8.

The post Oaklawn Extends Clenbuterol Ban to 120 Days Before Race appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

After Hair Test Drug Discoveries, Only Three Runners Contest Quarter Horse Futurity At Sam Houston

Friday night's $731,650 finals of the Sam Houston Futurity for 2-year-old Quarter Horses saw its field of 10 reduced to just three runners following the revelation that the prohibited drugs clenbuterol or albuterol were detected in hair samples in six entrants and two other test samples were considered inconclusive.

Juan Diaz Jr. trained the top two finishers in the race, Bh Inxs and Hock It To You, while Roberto Madrigal trained the third-place finisher, Lucky Dice.

Officials at Sam Houston Race Park in Houston, Texas, announced on Thursday, a day after the Paulick Report first reported the hair test findings, that the Futurity would be contested as a non-wagering event.

Apollitical Crystal, the fastest qualifier, was listed on the Equibase chart as a “trainer” scratch, while three other finalists trained by Adrian Huitron (El Gansito, Dr Toola and Coronas Candy Man) were listed as “veterinarian” scratches. The other “veterinarian” scratches were Mr de Capi (trained by Angel Sanchez), Hes Tempting Gl (Jose Garcia) and Dealalicious (Rodolfo Sanchez).

On Thursday, Sam Houston officials released the following statement:

The Texas Racing Commission (TxRC) performed two separate testing methods on the qualifiers for the Sam Houston Futurity.

· Post-race Blood and Urine samples on the qualifying nights (May 7 and May 8)

· Hair Test samples on May 15th

Throughout this time period, all qualifiers were required to remain on Sam Houston Race Park (SHRP) property until the conclusion of the finals. TxRC staff notified SHRP that all post-race samples were negative for the ten qualifying participants prior to entry day on May 21 for the Sam Houston Futurity Finals.

On Wednesday, May 26, TxRC staff informed Sam Houston Race Park of the following results from the hair testing performed on May 15:

· Six (6) positive results for either Clenbuterol and or Albuterol (both prohibited in Texas)

· Two (2) results were deemed inconclusive

· Two (2) results were negative

A second hair sample was taken on May 26 of those horses who tested positive or inconclusive.

Based on this information, and to protect the interest of the wagering public, Sam Houston Race Park will conduct the running of this race as a NON-WAGERING event and those Sam Houston Futurity participants will compete for purse money only.

Effective immediately and until further notice, Sam Houston Race Park will stop accepting future entries from those trainers whose horses tested positive. Entries have already been accepted through Thursday, June 3, 2021.

Sam Houston Race Park reserves the right to issue further disciplinary actions against the trainers of these horses, pending actions of the Texas Racing Commission, including the results of second hair test samples if applicable.

The post After Hair Test Drug Discoveries, Only Three Runners Contest Quarter Horse Futurity At Sam Houston appeared first on Horse Racing News | Paulick Report.

Source of original post

Verified by MonsterInsights